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compare patient-reported outcomes in two statins (Statin A and
Statin B). Medwatch is the Food and Drug Adminstration’s
(FDA) program for reporting serious reactions with drugs and
other medical products. Consumer reports are an increasing
number of those drug safety reports and through March 30,
2003, make up more than 27% of the total Medwatch reports.
METHODS: The QSCANTM software was used to compare the
consumer spontaneous reports of two statins (Statin A and Statin
B), using a signal detection methodology, the proportional
reporting ratio (PRR). The two statins were also individually
compared to the class of statin drugs. RESULTS: Statin A had
32,371 consumer reports of adverse events, and Statin B had a
total of 21,895 consumer reports through the ﬁrst quarter of
2003. Report dates were comparable for the two statins. Com-
pared to Statin B, Statin A had a signiﬁcantly higher proportion
of reports for arterial occlusion, cardiac arrest, increased blood
cholesterol, coronary artery surgery, transient ischemic attack,
and aggravated condition. Statin B had a signiﬁcantly higher
PRR for burning sensation (within nervous system disorders),
diabetes mellitus, and decreased blood pressure. The signiﬁcantly
elevated PRRs for Statin B persisted when compared to all other
statins, whereas Statin A appeared similar to the rest of the statin
class for these particular adverse event reports. CONCLU-
SIONS: Using drug safety signal detection data mining technol-
ogy of consumer-driven spontaneous reports, it is possible to
identify possible areas of drug differention between two drugs
or a single drug and an entire drug class. Consumer Medwatch
reports are spontaneous drug adverse event reports that are vol-
untarily submitted by the consumer and may be an informative
source of real-life patient reported outcomes.
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A survey of European Regulators conducted by the ERIQA
Group evidenced the need of training on HRQL and PRO. To
meet this need ERIQA in collaboration with the Cochrane
HRQL Methods Group proposed an Educational Program on
PRO and HRQL using the Workmats, designed for interactive
learning within a group to facilitate the understanding of key
concepts. In 2002 and 2003, regulators were trained in France
(AFSSAPS, ANAES), in Belgium (INAMI) and in the US (FDA).
Members of the Cochrane Collaboration were also trained
during the Stavanger and Barcelona colloquia. OBJECTIVES: To
assess the relevance and the impact of the Workmats training
from the regulators perspective. METHODS: We provided an
evaluation form at the end of each session. Seven questions were
asked addressing the content, the format and the attitude
towards PROs in the future. RESULTS: Eighty persons were
trained: thirty-two members of the Cochrane Collaboration and
48 regulators. To Question 2: Did you learn some useful infor-
mation? Ninety-seven and one-half percent answered Yes. To
Question 3: Did the workshop come up to your expectations?
Ninety-one and one-third percent answered Yes, 6.2% No and
2.5% did not answer. To Question 6: will this training change
your way of evaluating ﬁles? Ninety-oner and three-ﬁfths percent
of the regulators said Yes, 4.2% said No and 4.2% did not
answer. To Question 7: Would you recommend this workshop
to your colleagues? Sixty-eight and seven-tenths percent said yes,
21.3% said maybe, 3.7% said No and 6.3% did not answer.
CONCLUSION: Workmats proved to be a useful training tool
by providing basic information on PROs and enabling regula-
tors to better understand the ﬁeld. The fact that 91.6% of the
attendees said that this training might change their way of
reviewing ﬁles and 90% might recommend the session to 
colleagues encouraged us to plan sessions in 2004 in other 
European countries and the US.
PMD20
PRO INSTRUMENT DEVELOPMENT FOR RARE DISORDERS:
A FOCUS-ED APPROACH
Gold KF1,Tran KT1, Stephens JM1, Kimura A2
1Abt Associates Inc, Bethesda, MD, USA; 2Transkaryotic Therapies Inc,
Cambridge, MA, USA
OBJECTIVES: In the absence of a disease-speciﬁc instrument,
existing generic proﬁles may not be sensitive enough to measure
health-related quality of life in certain disease populations. In
addition, instruments developed for other diseases may have
some face validity but are not ideal. The goal of this research is
to develop an approach for rare disease instrument development
given the challenges of available sample and resources.
METHODS: The functional outcomes for clinical understanding
scale (FOCUS) “focuses” on aspects of rare diseases not captured
in validated instruments. A list of outcome domains is ﬁrst gen-
erated for the rare disorder. A validated instrument (“anchor”)
for a disease with some symptoms common to the rare disease
of interest is then identiﬁed. New items are developed in a similar
scale to the anchor instrument in order to allow joint scoring.
Data are collected to assess the validity and reliability for 1) the
anchor instrument; 2) new items (FOCUS) and 3) the anchor
instrument conjoined with the new items. RESULTS: A FOCUS
instrument was developed for Mucopolysaccharidosis II (MPSII;
Hunters Syndrome (HS)), a rare genetic disorder in children. The
childhood health assessment questionnaire (CHAQ) was selected
as the “anchor” instrument. Items of the HS-FOCUS were gen-
erated for MPSII indicators not covered by the CHAQ. Both the
CHAQ and the HS-FOCUS were tested in MPSII patients and
parents. Five of eight FOCUS domains had a Cronbach’s alpha
of at least 0.84 individually. The reliability of the overall CHAQ
score in MPSII patients was comparable to its original sample
(high 0.80s). The reliability of the CHAQ in conjunction with
the HS-FOCUS was superior to each in isolation. The compound
instrument also showed high face, external and statistical valid-
ity. CONCLUSIONS: This example illustrates the potential
success possible using this FOCUS methodology for meeting the
instrumentation needs for rare diseases.
METHODS
METHODS—Patient Preference Studies
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OBJECTIVES: The purpose of this study was to examine dif-
ferences between traders and non-traders and characteristics that
are associated with being a non-trader. When eliciting utilities
using the Time Trade-Off (TTO) method, studies have shown
that we can usually anticipate a high level (15–60%) of non-
traders—those people who are not willing to trade any of their
life for improved health. METHODS: A cross-sectional super-
vised self-administered survey was used to assess the perception
of health-related quality of life (HRQOL) and utilities using the
TTO method in the general population of 3 groups: Caucasian
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Americans (n = 441), African Americans (n = 344), Jamaicans (n
= 41). Each person was given one of three hypothetical health
states. Variables collected included: age, gender, race/ethnicity,
current and scenario HRQOL (on Likert and Visual Analogue
Scale (VAS)), TTO scores, and importance of religion. Chi square
and Mann-Whitney U tests were used to analyze the data.
RESULTS: Out of 823 participants, 83% were traders and 17%
were non-traders. Traders had signiﬁcantly higher proportions
of females (59%, p = 0.023), US whites (56%, p = 0.020), and
those who had ﬁnished college (30%, p = 0.013), whereas non-
traders had signiﬁcantly higher proportions of males (52%, p =
0.023), US blacks (52%, p = 0.020) and those who had only ﬁn-
ished high school (79%, p = 0.013). Non-traders had signiﬁ-
cantly lower average rank for age (p = 0.008) and higher average
rank for importance of religion (p = 0.034) than traders. There
was no signiﬁcant difference between traders and non-traders for
current HRQOL (Likert and VAS), but non-traders had signiﬁ-
cantly higher average rank for scenario HRQOL than traders 
(p < 0.0001). CONCLUSIONS: Younger age, male gender, com-
pleted high school but no college education, and higher impor-
tance of religion were signiﬁcantly associated with being a
non-trader. Non-traders perceive HRQOL associated with health
states as better compared to traders. Future studies employing
multivariate methods should be undertaken to determine the pre-
dictors of being a non-trader.
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OBJECTIVES: The objective of this project was to create and
test the acceptability and efﬁciency of a universal platform for
an automated survey collector in order to develop and imple-
ment a rapid, interactive computer-based collection of patient
data. METHODS: The mean age of the participants in this study
was 52 (range 35–69). The Automated Survey Collector (ASC)
tool was ﬁrst developed to be used as a universal platform. Using
qualitative analysis, this interactive data collection tool was then
used for pilot testing a TabletPC in patients with limited com-
puter experience. The study implemented the SF-12 Health
Survey (SF-12) and Health Utilities Index (HUI) self-adminis-
tered, quality of life questionnaires. Patients were given both
computer and paper versions of the survey, in random order.
Data on demographics and prior computer were also collected.
RESULTS: Of the 20 patients enrolled, 73% were male, 55%
had no employment and 82% had no previous computer expe-
rience. The qualitative analysis of the system acceptance showed
that it can be successfully implemented. All patients stated that
they prefer using ASC as a survey tool rather than the paper
version, and that it was “easy to use”. The majority of patients
(96%) claimed that operating ASC “was not complicated at all”
and 92% felt that it was “very easy to navigate through the
program”. In addition, time to complete the survey was respec-
tively 28% and 6% shorter for the computer versions of HUI
and SF-12. CONCLUSIONS: This pilot project showed that the
development and implementation of a universal platform, the
ASC, can have a successful implementation process on the basis
of a TabletPC in a population with minimal computer experi-
ence. The TabletPC is being explored as a feasible alternative for
effective data collection in clinical trials and engineering into the
workﬂow at the point of service.
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The use of preference-based measures in the evaluation of health
outcomes has extended considerably over the last decade. Their
alleged advantage over other types of general instruments in the
evaluation of health related quality of life (HRQOL), supposedly
lies in the fact that preference measures incorporate values or
utilities that reﬂects the value of social preferences through
health states. OBJECTIVES: The objective of this study was to
determine whether the use of social preference weights or utili-
ties makes any real difference when calculating scores for the
Euroqol (EQ5-D) questionnaire, a HRQOL preference-based
measure. METHODS: Responses to the EQ5-D of a sample of
10,972 patients from 10 countries enrolled in an observational
study of the treatment of schizophrenia in Europe were used for
this purpose. Two different methods of scoring the EQ-5D where
compared: “weighting the items” of the questionnaire through
the UK ofﬁcial weight coefﬁcients, and “non-weighting the
items”. Pearson’s, Spearman’s, and 2-way mixed parametric intr-
aclass correlation coefﬁcients were used to estimate the associa-
tion of the scores obtained in both ways. RESULTS: The
association between weighted and unweighted Euroqol scores
was extremely high (Pearson’s r = 0.91), as was the association
between their ranks (Spearman’s r = 0.93). The intraclass corre-
lation coefﬁcient obtained (0.89) also suggested that the con-
cordance between the score distributions was prominent.
CONCLUSIONS: A non-weighted approach to score the EQ5-
D is enough to explain a high proportion of variance in scores
obtained through the use of utilities. The differential contribu-
tion of weights based on population preference values is there-
fore minimal and, in our opinion, negligible.
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OBJECTIVE: To assess the potential value of individualizing
care based on patient preferences. Physician-patient interaction
often involves asymmetry of information. Efforts to facilitate
communication between physician and patients aim to overcome
this asymmetry of information in order to improve patient
welfare, but there is an important need to quantify the value of
such efforts. METHODS: In this presentation, we introduce the
concept of expected value of symmetry of information (EVSOI).
This represents the potential value of providing physicians infor-
mation on the preferences of individual patients, as reﬂected, for
example, in parameters such as QOL weights. We also show how
EVSOI varies with insurance structures that do not provide
incentives to internalize relative costs of treatments. We illustrate
this theory by calculating the EVSOI for physicians making treat-
ment choices for 65–69 year old prostate cancer patients.
RESULTS: Using a prostate cancer decision model, we ﬁnd the
annual EVSOI for 65–69 year old patients in the US is $529
million using a threshold of $100,000/QALY when physicians
maximize net health beneﬁts. Even when physicians only maxi-
mize health beneﬁts—that is they fail to internalize relative costs
of treatments—EVSOI remains to be quite large. CONCLU-
SIONS: The value of information on patient preference is large,
even when costs are not internalized. Future studies should
